Latest News Releases From The Newsroom
R100 Vector Deal Fuels 4DMT; ADC Therapeutics Tumbles On ZYNLONTA Trial Status
July 11th, 2023
Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT)(4DMT) have entered into a license agreement, allowing the use of 4DMT's intravitreal retinotropic R100 vector for rare monogenic ophthalmic diseases. This includes one initial ge. Read more
AspyreRx's Approval Boosts Better Therapeutics; Financial Figures, Outlook Drive WD-40, E2open
July 11th, 2023
Shares of Better Therapeutics, Inc. (Nasdaq: BTTX) surged over 20% in after-hours trading as the company received authorization from the FDA for its groundbreaking prescription-only digital therapeutic, AspyreRx. This innovative treatment offers cogn. Read more
CalAmp Posts Loss, Eyes Strategic Options; PriceSmart Posts Mixed Financial Figures
July 10th, 2023
CalAmp Corp. (Nasdaq: CAMP) faced a first-quarter fiscal 2024 loss of $0.11 per share, falling short of the consensus earnings per share estimate of $0.04. Looking ahead, the company expects Q2 FY24 revenues to range between $67 million and $73 mi. Read more
Market Surges: Mobilicom and Novavax See Dramatic Upswing
July 10th, 2023
Shares of Mobilicom Limited (Nasdaq: MOB) climbed over 100% in early trade following the company's announcement of a significant commercial-scale purchase order from Teledyne-FLIR, one of its Tier-1 customers. The purchase order from Teledyne Tech. Read more
Market Turmoil: FMC Slumps on Lowered Revenue Outlook
July 10th, 2023
Shares of FMC Corporation (NYSE: FMC) plummeted over 6% following the release of an update on its second quarter and full-year 2023 outlook. The company now expects second-quarter revenue to be in the range of $1.00 billion to $1.03 billion, signific. Read more
Helen of Troy Beats Estimates; Analysts Take Note of CAVA Group
July 10th, 2023
Helen of Troy Limited (Nasdaq: HELE) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.94, surpassing the consensus estimate of $1.60. Looking ahead, for the full-year fiscal 2024, the company expects adjusted EPS to fall . Read more
Q2: NanoString and ASE Technology Unveil Financial Figures
July 10th, 2023
NanoString Technologies, Inc. (Nasdaq: NSTG) has reported strong preliminary financial figures for the second quarter of 2023. The company expects Q2 revenue to surpass $44 million, reflecting a remarkable year-on-year growth of approximately 37%. Th. Read more
Nanobiotix Skyrockets On Multi-Million Dollar NBTXR3 Deal
July 10th, 2023
Shares of Nanobiotix S.A. (Nasdaq: NBTX) surged over 50% in pre-market trading following the announcement of a global licensing and commercialization agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson (NYSE: JNJ). The agree. Read more
Earnings Preview: MillerKnoll, AngioDynamics, and Theratechnologies
July 09th, 2023
On Wednesday, July 12, several companies are expected to report their financial results, including: MillerKnoll, Inc. (Nasdaq: MLKN), a consumer goods company, is set to release its financial results for the fourth quarter and full-year fiscal 202. Read more
Helen of Troy, WD-40, E2open, CalAmp, and VOXX Set to Release Earnings: A Preview
July 09th, 2023
Several companies are expected to report their financial results on Monday, July 10, including: Helen of Troy Limited (Nasdaq: HELE), a company operating in the consumer products industry, is set to release its first-quarter fiscal 2024 results be. Read more
Member Login